Lilly posts Phase 3 orforglipron results; two more programs report terminated-trial data

Eli Lilly had a busy week of registry updates, headlined by Phase 3 results for its oral GLP-1 orforglipron and two terminated trials reporting data, alongside two Phase 1 studies advancing.

• Orforglipron (LY3502970), a Phase 3 oral GLP-1 for obesity or overweight with type 2 diabetes, completed and posted results on 2026-09-04. The trial enrolled 1613 participants¹ and tested once daily oral orforglipron against placebo on body weight¹ over a planned 77 weeks with up to 22 visits¹.
• Lasmiditan (LY573144), a Phase 3 pediatric migraine study called PIONEER-PEDS1, was terminated and posted results on 2026-09-02. The study was designed to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine², with 847 participants enrolled²; the trial was terminated due to a strategic business decision².
• LY3549492, a Phase 2 study in obesity or overweight adults with type 2 diabetes conducted under a master protocol, was terminated and posted results on 2026-08-31. Enrollment was listed as 1 participant³, and the study was terminated for strategic business reasons³.
• Tirzepatide (LY3298176), a Phase 1 single-dose study in adults with type 1 diabetes and overweight or obesity, is now recruiting as of 2026-09-11. The study aims to learn how tirzepatide affects stomach emptying in this population⁴, with 18 participants planned⁴.
• LY5625575, a Phase 1 study in healthy participants (including Japanese and Chinese populations) and those with elevated C-reactive protein, is not yet recruiting, with a 2026-09 estimated start. The study will evaluate safety and tolerability in healthy participants and in those with elevated C-reactive protein⁵, with 204 participants estimated⁵.